---
figid: PMC2897908__nihms-209662-f0002
figlink: /pmc/articles/PMC2897908/figure/F2/
number: F2
caption: Schematic representation of key targets and pharmacological agents that inhibit
  MAPK signaling proteins. Imitanib, dastinib and sorafenib inhibit receptor tyrosine
  kinases thereby preventing activation of mitogen dependent activation in the MAPK
  pathway. Tipifarnib, R115777, BMS-214662 and L-778123 are selective to RAS while
  PLX4032, RAF-265 and XL281 specifically target activated B-RAF and are at various
  stages of clinical development. AZD6244, U0126, PD0325901, CI-1040, XL518, AZD8330,
  ARRY-162 and ARRY-300 inhibit MEK 1/2 while curcumin, plumbagin and DHMEQ target
  IKKβand NFκB.
pmcid: PMC2897908
papertitle: 'Targeting the MAPK Pathway in Melanoma: Why some approaches succeed and
  other fail.'
reftext: Gajanan S Inamdar, et al. Biochem Pharmacol. ;80(5):624-637.
pmc_ranked_result_index: '47115'
pathway_score: 0.7370867
filename: nihms-209662-f0002.jpg
figtitle: 'Targeting the MAPK Pathway in Melanoma: Why some approaches succeed and
  other fail'
year: ''
organisms:
- Homo sapiens
ndex: abebee69-df13-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2897908__nihms-209662-f0002.html
  '@type': Dataset
  description: Schematic representation of key targets and pharmacological agents
    that inhibit MAPK signaling proteins. Imitanib, dastinib and sorafenib inhibit
    receptor tyrosine kinases thereby preventing activation of mitogen dependent activation
    in the MAPK pathway. Tipifarnib, R115777, BMS-214662 and L-778123 are selective
    to RAS while PLX4032, RAF-265 and XL281 specifically target activated B-RAF and
    are at various stages of clinical development. AZD6244, U0126, PD0325901, CI-1040,
    XL518, AZD8330, ARRY-162 and ARRY-300 inhibit MEK 1/2 while curcumin, plumbagin
    and DHMEQ target IKKβand NFκB.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HRAS
  - KRAS
  - MAP2K2
  - MAPK3
  - BRAF
  - AKT1
  - MAP2K1
  - RAF1
  - NRAS
  - MAPK1
  - AKT3
  - AKT2
  - ARAF
  - plumbagin
  - U0126
  - R115777
  - BMS-214662
  - L-778123
  - PD0325901
  - AZD6244
  - Curcumin
genes:
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PIJK/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PIJK/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PIJK/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals:
- word: plumbagin
  source: MESH
  identifier: C014758
- word: U0126
  source: MESH
  identifier: C113580
- word: R115777
  source: MESH
  identifier: C402769
- word: BMS-214662
  source: MESH
  identifier: C415151
- word: L-778123
  source: MESH
  identifier: C425231
- word: PD0325901
  source: MESH
  identifier: C506614
- word: AZD6244
  source: MESH
  identifier: C517975
- word: Curcumin
  source: MESH
  identifier: D003474
diseases: []
figid_alias: PMC2897908__F2
redirect_from: /figures/PMC2897908__F2
figtype: Figure
---
